SEC Form 4 · accession 0000899243-19-003269
Apellis Pharmaceuticals, Inc. · APLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lukas Scheibler
Officer — See Remarks
Period of report
Feb 8, 2019
Accepted (ET)
Feb 12, 2019 · 4:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492422
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $13.85 | Feb 8, 2019 | A | 85,000 | A | — | Feb 7, 2029 | Common Stock | 85,000 | 85,000 | D |
Explanation of responses
- F1This option was granted on February 8, 2019 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.
Remarks
Executive Vice President of Research and Translational Medicine